As of Friday close, Iovance Biotherapeutics Inc.’s (NASDAQ:IOVA) stock was down -$0.16, moving down -3.28 percent to $4.87. The average number of shares traded per day over the past five days has been 10,325,140 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.40 fall in that time frame. In the last twenty days, the average volume was 8,347,880, while in the previous 50 days, it was 6,006,162.
Since last month, IOVA stock retreated -22.82%. Shares of the company fell to $4.41 on 09/14/23, the lowest level in the past month. A 52-week high of $10.41 was reached on 05/23/23 after having rallying from a 52-week low of $4.41. Since the beginning of this year, IOVA’s stock price has dropped by -23.79% or -$1.52, and marked a new high 8 times. However, the stock has declined by -53.22% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
IOVA stock investors should be aware that Iovance Biotherapeutics Inc. (IOVA) stock had its last reported insider trading activity 5 days ago on Sep 18. MCPEAK MERRILL A, the Director of the company, purchased of 10,000 shares for $5.56 on Sep 18. It resulted in a $55,600 investment by the insider. Rothbaum Wayne P. added 5,000,000 shares at an average price of $5.30 on Sep 15. The insider now owns 23,067,333 shares following the transaction. On Dec 21, Director MCPEAK MERRILL A bought 10,000 shares at $6.15 apiece. The transaction was valued at $61,500.
Valuation Metrics
The stock’s beta is 0.13. Besides these, the trailing price-to-sales (P/S) ratio of 5317.80, the price-to-book (PB) ratio of 1.89.
Financial Health
In the three months ended June 29, Iovance Biotherapeutics Inc.’s quick ratio stood at 3.00, while its current ratio was 3.10, showing that the company is able to pay off its debt.
In Iovance Biotherapeutics Inc.’s quarter-end financial report for June 29, it reported total debt of $1.0 million. IOVA’s revenue rose 100.0% during the quarter, while net income inched up to $0.24 million. While analysts expected Iovance Biotherapeutics Inc. to report -$0.8 quarterly earnings, the actual figure was -$0.47 per share, beating the consensus estimate by 41.30%. During the quarter, the company generated -$101.27 million in EBITDA. The liabilities of Iovance Biotherapeutics Inc. were 178.72 million at the end of its most recent quarter ended June 29, and its total debt was $80.71 million. The value of shareholders’ equity is $247.78 million.
Technical Picture
This quick technical analysis looks at Iovance Biotherapeutics Inc.’s (IOVA) price momentum. With a historical volatility rate of 138.50%, the RSI 9-day stood at 34.83% on 22 September.
With respect to its five-day moving average, the current Iovance Biotherapeutics Inc. price is down by -7.59% percent or -$0.40. At present, IOVA shares trade -19.90% below its 20-day simple moving average and -24.26% percent below its 100-day simple moving average. However, the stock is currently trading approximately -36.59% below its SMA50 and -39.35% below its SMA200.
Stochastic coefficient K was 31.15% and Stochastic coefficient D was 42.02%, while ATR was 0.51. Given the Stochastic reading of 22.33% for the 14-day period, the RSI (14) reading has been calculated as 35.83%. As of today, the MACD Oscillator reading stands at -0.26, while the 14-day reading stands at -0.49.
Analyst Ratings
Barclays reiterated its an Overweight rating on Iovance Biotherapeutics Inc. (NASDAQ: IOVA) in a note to investors. The analysts firm has however raised their price target to $18, representing a possible 87.83% increase in the stock price. Iovance Biotherapeutics Inc. (IOVA) has been rated Buy by analysts. According to 0 brokerage firms, IOVA is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 2 analysts rate Iovance Biotherapeutics Inc. stock as buy, with 10 recommending it as overweight.
With a median target price of $20.00, the current consensus forecast for the stock is $14.00 – $38.00. Based on these forecasts, analysts predict Iovance Biotherapeutics Inc. (IOVA) will achieve an average price target of $22.36.
